View Post

Mature Data Drive New Insights With Novel Agents in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic. The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates (ADCs), and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic, explained Lisa A. Carey, MD, FASCO. …

View Post

Overcoming Mechanisms of Resistance to CDK4/6, PI3K Inhibition in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Hayley Virgil From: onclive.com Cynthia X. Ma, MD, PhD, discusses several research efforts examining mechanisms of resistance to CDK4/6 and PI3K inhibitors in breast cancer and some of the novel combinations that may possess the potential to overcome this challenge. Although survival outcomes have improved for patients with metastatic estrogen receptor (ER)–positive breast cancer with the addition of CDK4/6 …

View Post

Keto Claims: Can Diet Be a Form of Cancer Therapy?

In Clinical Studies News by Barbara Jacoby

By: Matthew Tontonoz From: mskcc.org An MSK doctor weighs in on a recent study that links a ketogenic diet to improved responses to certain cancer drugs. In July 2018, researchers from Weill Cornell Medicine and Columbia University published the results of a laboratory study that combined a very low-carbohydrate diet with targeted drugs called PI3K inhibitors as a treatment for cancer. …